SGLT
Sodium-dependent glucose cotransporters
SGLTs (Sodium-dependent glucose cotransporters) are a family of glucose transporters and contribute to glucose reabsorption. The two most well-known members of SGLT family are SGLT1 and SGLT2, which are members of the SLC5A gene family. The two transporters are of primary importance for glucose homeostasis by absorbing glucose from the diet in the small intestine (via SGLT1) and by reabsorbing the filtered glucose in the tubular system of the kidney (primarily SGLT2; to smaller extent via SGLT1); the latter process returns glucose into the blood stream and prevents urinary glucose loss. SGLT1 and SGLT2 have been proposed as a novel therapeutic strategy for diabetes and cardiomyopathy.
SGLT Isoform Specific Products
All Product Categories
-
SGLT Related Products (97)
Related Products (97)
-
SGLT Isoform Comparison
-
YM-543
0 ImagesCat. No.: HY-125327CAS No.: 1610007-47-0YM-543 is a selective SGLT2 inhibitor that effectively reduces hyperglycemia in type 2 diabetic mice through increased urinary glucose excretion. YM-543 demonstrates potent inhibition of both mouse and human SGLT2 activities at nanomolar concentrations. YM-543, when administered orally, significantly improves glucose tolerance in diabetic models and sustains its effects for over 12 hours. YM-543, in combination with other antidiabetic agents like rosiglitazone or metformin, enhances the therapeutic effects on diabetic symptoms. YM-543 does not affect blood glucose levels in normal mice, indicating its specificity for diabetic conditions.
-
LX2761
0 ImagesCat. No.: HY-101122CAS No.: 1610954-97-6LX2761 is an orally active, dual SGLT1/SGLT2 inhibitor with IC50 values of 2.2 nM and 2.7 nM against human SGLT1 and SGLT2, respectively. LX2761 locks human SGLT1 in an outward-open conformation and blocks its putative water permeation pathway. After oral administration, LX2761 is confined exclusively to the intestinal lumen, delays intestinal glucose absorption, regulates intestinal glucose metabolism, increases cecal glucose levels, reduces cecal pH, improves glycemic control and elevates plasma total GLP-1 levels. However, LX2761 induces diarrhea in a dose-dependent manner. LX2761 can be used in diabetes-related research.
-
SAR-7226
0 ImagesCat. No.: HY-150322CAS No.: 702638-25-3
-
Mizagliflozin (sebacate)
0 ImagesCat. No.: HY-17638ACAS No.: 1169392-27-1Synonyms: DSP-3235 (sebacate); KGA-3235 (sebacate); GSK-1614235 (sebacate)Mizagliflozin sebacate (DSP-3235 sebacate) is a sodium-glucose cotransporter inhibitor with activity in improving vascular cognitive impairment caused by small vessel disease. Mizagliflozin sebacate improves blood flow and reverses vascular cognitive impairment by inhibiting neuronal SGLT1 activity. Mizagliflozin sebacate also showed the ability to increase the survival rate of IL-1β-treated PC12HS cells. Mizagliflozin sebacate promotes improvements in spatial learning and memory caused by small vessel disease in mouse models.
-
Pragliflozin-13C6
0 ImagesCat. No.: HY-14894S2CAS No.: 2743031-48-1Synonyms: ASP1941-13C6Pragliflozin-13C6 (ASP1941-13C6) is 13C labeled Ipragliflozin. Ipragliflozin (ASP1941) is an orally active and selective SGLT2 inhibitor with IC50s of 7.38 and 1876 nM, 6.73 and 1166 nM, 5.64 and 1380 nM for human SGLT2 and SGLT1, rat SGLT2 and SGLT1, mouse SGLT2 and SGLT1, respectively. Antidiabetic agent.
-
Velagliflozin proline hydrate
0 ImagesVelagliflozin proline hydrate is the clinical form of Velagliflozin (HY-109018). Velagliflozin is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor with antidiabetic activity. Velagliflozin reduces renal glucose reabsorption and stimulates glycosuria, which lowers blood sugar and insulin concentrations.
-
Janagliflozin
0 ImagesCat. No.: HY-178734CAS No.: 1800115-22-3Janagliflozin is orally active and highly selective sodium-glucose cotransporter 2 (SGLT2) inhibitor (IC50=0.0058 μM for SGLT2 and 4.802 μM for SGLT1). Janagliflozin inhibits SGLT2 in the proximal renal tubules, reducing glucose reabsorption and promoting urinary glucose excretion (UGE) to lower blood glucose levels. Janagliflozin is promising for research of type 2 diabetes mellitus.
-
TA-1887
0 ImagesCat. No.: HY-12608CAS No.: 1003005-29-5Synonyms: JNJ-39933673TA-1887 (JNJ-39933673) is a highly potent, selective and orally active SGLT2 inhibitor (IC50: 1.4 nM) with antihyperglycemic effects. TA-1887 can be used in the research of diabetes.
-
SGLT2-IN-3
0 ImagesCat. No.: HY-178167SGLT2-IN-3 is a sodium-glucose co-transporter 2 (SGLT2) inhibitor. SGLT2-IN-3 can inhibit glucose uptake. SGLT2-IN-3 can be used for the research of metabolic disease, such as diabetes.
-
Dapagliflozin ((2S)-1,2-propanediol, hydrate) (Standard)
0 ImagesSynonyms: BMS-512148 (2S)-1,2-propanediol, hydrate (Standard)Dapagliflozin ((2S)-1,2-propanediol, hydrate) (Standard) is the analytical standard of Dapagliflozin ((2S)-1,2-propanediol, hydrate). This product is intended for research and analytical applications. Dapagliflozin ((2S)-1,2-propanediol, hydrate) is the S-enantiomer of Dapagliflozin 1,2-propanediol, hydrate. Dapagliflozin ((2S)-1,2-propanediol, hydrate), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine. Dapagliflozin ((2S)-1,2-propanediol, hydrate) induces HIF1 expression and attenuates renal IR injury.
-
Dapagliflozin methyl acetate
0 ImagesCat. No.: HY-Z0437CAS No.: 1632287-34-3Dapagliflozin methyl acetate is an orally active SGLT2 inhibitor. Dapagliflozin methyl acetate may be used in type 2 diabetes research.
-
YM543 free base
0 ImagesCat. No.: HY-122613CAS No.: 655237-16-4YM543 free base is a potent and orally active sodium-glucose cotransporter (SGLT) 2 inhibitor. YM543 free base reduces blood glucose levels. YM543 free base can be used in research of diabetes.
-
Sotagliflozin (Standard)
0 ImagesSynonyms: LX-4211 (Standard); LP-802034 (Standard)Sotagliflozin (Standard) is the analytical standard of Sotagliflozin. This product is intended for research and analytical applications. Sotagliflozin (LX-4211) is a potent dual SGLT2/1 inhibitor. Antidiabetic agents.
-
HSK0935 (Standard)
0 ImagesCat. No.: HY-101782RCAS No.: 1638851-44-1HSK0935 (Standard) is the analytical standard of HSK0935 (HY-101782). This product is intended for research and analytical applications. HSK0935 is a potent, highly selective and orally available SGLT2 inhibitor with an IC50 of 1.3 nM. Antihyperglycemic activities.
-
Trilobatin (Standard)
0 ImagesTrilobatin (Standard) is the analytical standard of Trilobatin. This product is intended for research and analytical applications. Trilobatin, a natural sweetener derived from?Lithocarpus polystachyus?Rehd, Trilobatin?is an HIV-1 entry inhibitor targeting the HIV-1 Gp41 envelope. Neuroprotective effects. Trilobatin is also a SGLT1/2 inhibitor that selectively induces the proliferation of human hepatoblastoma cells.
-
SGLT2-IN-5
0 ImagesCat. No.: HY-180527SGLT2-IN-5 (Compound 99) is an orally active SGLT2 inhibitor with IC₅₀ values for SGLT2, SGLT1, and DPP4 of 0.8, 23, and 58 nM respectively. SGLT2-IN-5 controls blood sugar levels in diabetic rat models and increases the levels of active GLP-1. SGLT2-IN-5 can be used for the study of type 2 diabetes.
-
Velagliflozin proline hydrate (Standard)
0 ImagesCat. No.: HY-109018BRCAS No.: 1661838-94-3Velagliflozin proline hydrate (Standard) is the analytical standard of Velagliflozin (proline hydrate) (HY-109018B). This product is intended for research and analytical applications. Velagliflozin proline hydrate is the clinical form of Velagliflozin (HY-109018). Velagliflozin is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor with antidiabetic activity. Velagliflozin reduces renal glucose reabsorption and stimulates glycosuria, which lowers blood sugar and insulin concentrations.
-
Enavogliflozin (Standard)
0 ImagesCat. No.: HY-109144RCAS No.: 1415472-28-4Synonyms: DWP-16001 (Standard)Enavogliflozin (Standard) is the analytical standard of Enavogliflozin (HY-109144). This product is intended for research and analytical applications. Enavogliflozin (DWP-16001), an antidiabetic agent, is an orally active, best-in-class and selective sodium-glucose cotransporter-2 (SGLT-2) inhibitor.
-
SGLT2-IN-1 (Standard)
0 ImagesCat. No.: HY-I1120RCAS No.: 864070-37-1SGLT2-IN-1 (standard) is the analytical standard for SGLT2-IN-1. This product is used for research and analytical applications. SGLT2-IN-1 (Compound 5) is an inhibitor for sodium-dependent glucose cotransporter (SGLT2), with IC50 of 33 nM in CHO cells transfected with human SGLT2. SGLT2-IN-1 is selective for SGLT2 over SGLT1. SGLT2-IN-1 is an active metabolite of dapagliflozinactive metabolite of dapagliflozin.
-
Licogliflozin (Standard)
0 ImagesCat. No.: HY-109092RCAS No.: 1291094-73-9Synonyms: LIK066 (Standard)Licogliflozin (Standard) is the analytical standard of Licogliflozin (HY-109092). This product is intended for research and analytical applications. Licogliflozin is a sodium glucose cotransporter (SGLT1 and SGLT2) inhibitor.
